跨性别人群接受激素治疗的静脉血栓栓塞风险:一项系统综述

Anabel Franco-Moreno , Pablo Ryan , Nuria Muñoz-Rivas , Jorge Valencia , Juan Torres-Macho , Susana Bacete-Cebrián
{"title":"跨性别人群接受激素治疗的静脉血栓栓塞风险:一项系统综述","authors":"Anabel Franco-Moreno ,&nbsp;Pablo Ryan ,&nbsp;Nuria Muñoz-Rivas ,&nbsp;Jorge Valencia ,&nbsp;Juan Torres-Macho ,&nbsp;Susana Bacete-Cebrián","doi":"10.1016/j.medcle.2025.106921","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.</div></div><div><h3>Materials and method</h3><div>A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; <em>p</em> <!-->&lt;<!--> <!-->0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; <em>p</em> <!-->=<!--> <!-->0.60) were found.</div></div><div><h3>Conclusion</h3><div>Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.</div></div>","PeriodicalId":74154,"journal":{"name":"Medicina clinica (English ed.)","volume":"164 12","pages":"Article 106921"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of venous thromboembolism in the transgender population on hormone therapy: A systematic review\",\"authors\":\"Anabel Franco-Moreno ,&nbsp;Pablo Ryan ,&nbsp;Nuria Muñoz-Rivas ,&nbsp;Jorge Valencia ,&nbsp;Juan Torres-Macho ,&nbsp;Susana Bacete-Cebrián\",\"doi\":\"10.1016/j.medcle.2025.106921\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and objective</h3><div>Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.</div></div><div><h3>Materials and method</h3><div>A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.</div></div><div><h3>Results</h3><div>Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; <em>p</em> <!-->&lt;<!--> <!-->0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; <em>p</em> <!-->=<!--> <!-->0.60) were found.</div></div><div><h3>Conclusion</h3><div>Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.</div></div>\",\"PeriodicalId\":74154,\"journal\":{\"name\":\"Medicina clinica (English ed.)\",\"volume\":\"164 12\",\"pages\":\"Article 106921\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina clinica (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2387020625002682\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2387020625002682","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的激素治疗与血栓形成风险增加有关。本系统综述的目的是评估接受性别确认激素治疗的跨性别人群静脉血栓栓塞的发生率,并将其与出生时性别相同的顺性别个体进行比较。材料和方法在PubMed、Cochrane Library、Scopus和EMBASE等数据库中进行文献检索,包括所有报告激素治疗跨性别者静脉血栓栓塞发生率的研究。结果共纳入21项研究。五项研究评估了两种人群中血栓栓塞事件的发生率。跨性别女性血栓的发生率高于顺性男性(OR 2.23;95% ci: 1.93-2.57;p & lt;0.001)。跨性别男性与顺性别女性无差异(OR 0.96;95% ci: 0.87-2.31;P = 0.60)。结论本系统综述提示,激素治疗可增加跨性别女性发生静脉血栓栓塞的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Risk of venous thromboembolism in the transgender population on hormone therapy: A systematic review

Background and objective

Hormone therapy is associated with an increased thrombotic risk. The objective of this systematic review is to assess the incidence of venous thromboembolism in the transgender population undergoing gender-affirming hormone therapy and compare it with that in cisgender individuals of the same sex assigned at birth.

Materials and method

A literature search was conducted in databases including PubMed, Cochrane Library, Scopus, and EMBASE, encompassing all studies that report data related to the incidence of venous thromboembolism in transgender individuals on hormone therapy.

Results

Twenty-one studies were included. Five studies assessed the incidence of thromboembolic events in both populations. The occurrence of thrombosis was higher in transgender women than cisgender men (OR 2.23; 95% CI: 1.93–2.57; p < 0.001). No differences between transgender men and cisgender women (OR 0.96; 95% CI: 0.87–2.31; p = 0.60) were found.

Conclusion

Our systematic review suggests that hormone therapy in transgender women may increase the risk of venous thromboembolism.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信